Sanjurjo, A. D., Pro, B., & Cherng, H.-J. J. (2025). Highlights of American Society of Hematology 2024—lymphoma. The Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf166

Ruemmele, T., Macedo, R., Stein, M. N., Chan, H. T., Mapara, M. Y., Jacquemont, C. F., & Reshef, R. (2025). Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1543622

Shadman, M., Brown, J. R., Mohseninejad, L., Yang, K., Burnett, H., Neupane, B., Williams, R., Lamanna, N., O’Brien, S. M., Tedeschi, A., & Tam, C. S. (2025). Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014523

Karmali, R., Shouse, G., Torka, P., Moyo, T. K., Romancik, J., Barta, S. K., Bhansali, R., Cohen, J. B., Shah, N. N., Zurko, J., Kenkre, V. P., Hess, B., Stephens, D. M., Fitzgerald, L., Ollila, T., Tabiti, B., Roy, I., Ma, S., Winter, J., … Epperla, N. (2025). Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy. Blood Cancer Journal, 15(1). https://doi.org/10.1038/s41408-025-01250-8

Brown, J. R., Li, J., Eichhorst, B., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Huang, R., Shi, Y., Idoine, A., Salmi, T., Cohen, A. C., & Shadman, M. (2025). ACQUIRED MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY CLL WHO PROGRESSED IN THE ALPINE STUDY. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014206

Marks, L. J., Ritter, V., Agrusa, J., Kamdar, K. Y., Rivers, J., Gardner, R. A., Ehrhardt, M. J., Devine, K. J., Phillips, C. A., Reilly, A. F., August, K., Weinstein, J. L., Satwani, P., Forlenza, C. J., Smith, C. M., Greer, C., Afify, Z., Lin, C. H., Belsky, J. A., … Aftandilian, C. (2025). Pediatric relapsed/refractory ALK+ anaplastic large cell lymphoma treatment and outcomes in the targeted drug era. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014745

Geskin, L., Querfeld, C., Hodak, E., Nikbakht, N., Papadavid, E., Ardigò, M., Wehkamp, U., & Bagot, M. (2024). Chlormethine Gel for Treatment of Patients with Mycosis Fungoides: Best Practices and Guidance to Clinicians. Dermatology and Therapy. https://doi.org/10.1007/s13555-024-01305-x

Han, J. X., Koh, M. J., Boussi, L., Sorial, M., McCabe, S. M., Peng, L., Singh, S., Eche-Ugwu, I. J., Gabler, J., Fernandez Turizo, M. J., MacVicar, C. T., Garg, A. R., Disciullo, A., Chopra, K., Lenart, A. W., Nwodo, E., Barnes, J. A., Koh, M. J., Miranda, E. C. M., … Jain, S. (2024). Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014674

Lamanna, N., Tam, C. S., Woyach, J. A., Alencar, A. J., Palomba, M. L., Zinzani, P. L., Flinn, I. W., Fakhri, B., Cohen, J. B., Kontos, A., Konig, H., Ruppert, A. S., Chatterjee, A., Sizelove, R., Compte, L., Tsai, D. E., & Jurczak, W. (2024). Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy. EJHaem, 5(5), 929–939. Portico. https://doi.org/10.1002/jha2.1013

Yu, C., Shen, Q., Holmes, A. B., Mo, T., Tosato, A., Soni, R. K., Corinaldesi, C., Koul, S., Pasqualucci, L., Hussein, S., Forouhar, F., Dalla-Favera, R., & Basso, K. (2024). MEF2B C-terminal mutations enhance transcriptional activity and stability to drive B cell lymphomagenesis. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-51644-8

Nikiforow, S., Whangbo, J. S., Reshef, R., Tsai, D. E., Bunin, N., Abu-Arja, R., Mahadeo, K. M., Weng, W.-K., Van Besien, K., Loeb, D., Nasta, S. D., Nemecek, E. R., Zhao, W., Sun, Y., Galderisi, F., Wahlstrom, J., Mehta, A., Gamelin, L., Dinavahi, R., & Prockop, S. (2024). Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Advances, 8(12), 3001–3012. https://doi.org/10.1182/bloodadvances.2023011626

Song, A., Li, J. Y., Cockey, S. G., Shao, R., & Zhang, H. (2024). EBV‐Positive Pleomorphic Variant Transformation of CD5‐Negative Mantle Cell Lymphoma: A Rare Case Report and Literature Review. Case Reports in Hematology, 2024(1). Portico. https://doi.org/10.1155/2024/3267739

Shiyanbola, O., Nigdelioglu, R., Dhall, D., González, I. A., Warmke, L. M., Schechter, S., Choi, W.-T., Hu, S., Voltaggio, L., Zhang, Y., Liang, T. Z., Ko, H. M., Charville, G. W., & Longacre, T. A. (2024). Extraskeletal Ewing Sarcoma of the Gastrointestinal and Hepatobiliary Tract. American Journal of Surgical Pathology. https://doi.org/10.1097/pas.0000000000002236

Vilarello, B. J., Jacobson, P. T., Gudis, D. A., & Overdevest, J. B. (2024). B-cell Lymphoblastic Lymphoma Presenting as a Sinonasal Mass: A Case Report. Cureus. https://doi.org/10.7759/cureus.58132

Dar, N., Roberts, N., Gru, A., Obiorah, I., Zheng, J., Shields, L. K., Cropley, T., & Marchi, E. (2024). Tumor flare reaction in a patient with mycosis fungoides treated with a novel immune-epigenetic doublet. JAAD Case Reports, 48, 18–22. https://doi.org/10.1016/j.jdcr.2024.03.016

Schöffski, P., Lorusso, P., Yamamoto, N., Reichardt, P., Schwartz, L., Dercle, L., Zhao, B., Chitalia, R., Montgomery, G., Hu, C., Landsteiner, H. T., Jayadeva, G., & Gounder, M. (2024). 56O A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma. ESMO Open, 9, 102446. https://doi.org/10.1016/j.esmoop.2024.102446

Brown, J. R., Ghia, P., Jurczak, W., Kahl, B. S., Lamanna, N., Robak, T., Shadman, M., Tam, C. S., Qiu, L., Paik, J., Salmi, T., Wang, L., Zhang, J., Zhang, M., Cohen, A., Ma, H., & Tedeschi, A. (2024). Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database. Haematologica. https://doi.org/10.3324/haematol.2023.283846

Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Oluwole, O. O., Yakoub-Agha, I., Khanal, R., Rosenblatt, J., Korn, R., Peng, W., Lui, C., … Jacobson, C. A. (2024). Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood, 143(6), 496–506. https://doi.org/10.1182/blood.2023021243

Olsen, E. A., Hodak, E., Geskin, L., & Scarisbrick, J. (2024). Bridging the specialty gap: Update on primary cutaneous lymphomas. Journal of the American Academy of Dermatology, 90(2), 257–260. https://doi.org/10.1016/j.jaad.2023.10.007

Shih, B. B., Ma, C., Cortes, J. R., Reglero, C., Miller, H., Quinn, S. A., Albero, R., Laurent, A. P., Mackey, A., Ferrando, A. A., Geskin, L., & Palomero, T. (2024). Romidepsin and Afatinib Abrogate Jak–Signal Transducer and Activator of Transcription Signaling and Elicit Synergistic Antitumor Effects in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 144(7), 1579-1589.e8. https://doi.org/10.1016/j.jid.2023.12.010

Cherng, H.-J. J., & Herrera, A. (2024). Now You “CD20,” Now You Don’t: A Vanishing Act in B-cell Lymphomas After Bispecific Antibody Treatment. The Hematologist, 21(2). https://doi.org/10.1182/hem.v21.2.202425

O’Neil, D. S., Martei, Y. M., Crew, K. D., Castillo, B. S., Costa, P., Lim, T., Michel, A., Rubin, E., Goel, N., Hurley, J., Lopes, G., & Antoni, M. H. (2023). Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV. JAMA Network Open, 6(12), e2346223. https://doi.org/10.1001/jamanetworkopen.2023.46223

Diefenbach, C. S., Jegede, O., Ansell, S. M., Steidl, C., Natkunam, Y., Scott, D. W., Mehta-Shah, N., Amengual, J. E., Forlenza, C. J., Cole, P. D., Bartlett, N. L., David, K. A., Advani, R. H., Ambinder, R. F., Thomas, S., Ibrahimi, S., & Kahl, B. S. (2023). Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412). Blood, 142(Supplement 1), 607–607. https://doi.org/10.1182/blood-2023-184531

Lin, W.-H. W., Rodriguez Cortes, J., Aitken, M., Reglero, C., Laurent, A., Cooke, A., Belver, L., Bhagat, G., Rabadan, R., Ferrando, A. A., & Palomero, T. (2023). Role of the S1P Signaling Pathway in the Pathogenesis of Angioimmunoblastic T-Cell Lymphoma. Blood, 142(Supplement 1), 526–526. https://doi.org/10.1182/blood-2023-174090

Bagot, M., Kim, Y. H., Geskin, L. J., Ortiz-Romero, P. L., Kim, E., Mehta-Shah, N., Dereure, O., Oro, S., Beylot-Barry, M., Dalle, S., Jacobsen, E., Lansigan, F., Ram-Wolff, C., Khodadoust, M. S., Battistella, M., Gru, A. A., Moins-Teisserenc, H., Zinzani, P. L., Viotti, J., … Porcu, P. (2023). Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial. Blood, 142(Supplement 1), 185–185. https://doi.org/10.1182/blood-2023-173806

Tolu, S. S., Gribbin, C., Seshadri, M. R., Chen, Z., Orlando, E., Grenet, J., Toor, R., Sanjurjo, A., Phillips, A. A., Shore, T. B., Martin, P., Leonard, J. P., Pro, B., Amengual, J. E., & Ruan, J. (2023). Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL. Blood, 142(Supplement 1), 1698–1698. https://doi.org/10.1182/blood-2023-178231

Deluca, C., Beyer, M., Drew, H., Murray, J., Massey, J., Koffman, B., Battiato, K., Gribben, J. G., Lamanna, N., & Russomanno, C. (2023). The Value of Collaboration with Patient Advocacy Organizations to Enhance Initiatives Focused on Patient-Centered Care and Improve Outcomes in Chronic Lymphocytic Leukemia. Blood, 142(Supplement 1), 3715–3715. https://doi.org/10.1182/blood-2023-177959

Fahmy, L. M., Yang, H. R., Zhou, M., Beylergil, V., Schreidah, C. M., Bilgrami, Z., Kwinta, B. D., Schwartz, L., Fojo, A. T., Bates, S. E., & Geskin, L. J. (2023). Dynamic Changes in Lymph Node Size and Skin Scoring Predict Response to Treatment in CTCL: An Interim Analysis. Blood, 142(Supplement 1), 4443–4443. https://doi.org/10.1182/blood-2023-189493

Salles, G., Park, S. I., Phillips, T. J., Amengual, J. E., Andorsky, D. J., Campbell, P., McKay, P., Leonard, J. P., Chen, Y., Chen, J., Bannerji, R., Kapopara, A., Szanto, A., & Morschhauser, F. (2023). Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up. Blood, 142(Supplement 1), 3035–3035. https://doi.org/10.1182/blood-2023-179910

Coombs, C. C., Woyach, J. A., Brown, J. R., Ghia, P., Roeker, L. E., Patel, K., Eyre, T. A., Tam, C. S., Seymour, J. F., Shah, N. N., Flinn, I. W., Cheah, C. Y., Ma, S., Rhodes, J. M., Izutsu, K., Jurczak, W., Wierda, W. G., Loubert, A., Payakachat, N., … Lamanna, N. (2023). Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study. Blood, 142(Supplement 1), 6535–6535. https://doi.org/10.1182/blood-2023-186145

Khatiwada, P., Soni, M., & Muranski, P. (2023). Highly Active Cytotoxic CD4 + T Cells Targeting EBV Oncoproteins with Enhanced In Vivo Anti-Tumor and Self-Renewal Properties. Blood, 142(Supplement 1), 3464–3464. https://doi.org/10.1182/blood-2023-190690

Xu-Monette, Z. Y., Li, Y., Snyder, T., Yu, T., LU, T., Tzankov, A., Visco, C., Bhagat, G., Qian, W., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F., Go, H., Ponzoni, M., Ferreri, A. J. M., Møller, M., … Young, K. H. (2023). Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma. Blood, 142(Supplement 1), 429–429. https://doi.org/10.1182/blood-2023-179972

Tolu, S. S., Sanjurjo, A., Destephano, D., Pro, B., & Amengual, J. E. (2023). Outcomes in Minorities with PTCL By Clinical Trial Enrollment. Blood, 142(Supplement 1), 4431–4431. https://doi.org/10.1182/blood-2023-177722

Tolu, S. S., Piorczynski, T. B., Pazos, M., Estrella, B., Huang, W., Ryu, Y. K., Cherng, H.-J. J., Pro, B., & Amengual, J. E. (2023). JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity. Blood, 142(Supplement 1), 6118–6118. https://doi.org/10.1182/blood-2023-180875

Tam, C. S., Lamanna, N., O’Brien, S. M., Qiu, L., Yang, K., Barnes, G., Wu, K., Salmi, T., & Brown, J. R. (2023). Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial. Current Medical Research and Opinion, 39(11), 1497–1503. https://doi.org/10.1080/03007995.2023.2262378

Jain, M. D., Miklos, D. B., Jacobson, C. A., Timmerman, J. M., Sun, J., Nater, J., Fang, X., Patel, A., Davis, M., Heeke, D., Trinh, T., Mattie, M., Neumann, F., Kim, J. J., To, C., Filosto, S., & Reshef, R. (2023). Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11. Clinical Cancer Research, 29(20), 4118–4127. https://doi.org/10.1158/1078-0432.ccr-23-0916

Ruan, J., Zain, J., Palmer, B., Jovanovic, B., Mi, X., Swaroop, A., Winter, J. N., Gordon, L. I., Karmali, R., Moreira, J., Petrich, A. M., & Pro, B. (2023). Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Advances, 7(19), 5771–5779. https://doi.org/10.1182/bloodadvances.2023009767

O’Neil, D. S., Ayeni, O. A., Farrow, H. A., Chen, W. C., Demetriou, G., Buccimazza, I., Čačala, S., Stopforth, L. W., Joffe, M., Antoni, M. H., Lopes, G., Pumpalova, Y. S., Mapanga, W., Jacobson, J. S., Crew, K. D., Neugut, A. I., Ruff, P., & Cubasch, H. (2023). The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast Cancer. The Oncologist, 28(10), e921–e929. https://doi.org/10.1093/oncolo/oyad056

Zhou, N., Choi, J., Grothusen, G., Kim, B.-J., Ren, D., Cao, Z., Liu, Y., Li, Q., Inamdar, A., Beer, T., Tang, H.-Y., Perkey, E., Maillard, I., Bonasio, R., Shi, J., Ruella, M., Wan, L., & Busino, L. (2023). DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance. Blood, 142(11), 973–988. https://doi.org/10.1182/blood.2022018752

Muehlenbein, C. E., Coombs, C. C., Shah, N. N., Jurczak, W., Woyach, J., Cheah, C. Y., Patel, K., Maddocks, K., Wang, Y., Wang, C., Abhyankar, S., Tsai, D. E., & Eyre, T. A. (2023). POSTER: CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies. Clinical Lymphoma Myeloma and Leukemia, 23, S229. https://doi.org/10.1016/s2152-2650(23)00883-2

Castellino, S. M., Giulino‐Roth, L., Harker‐Murray, P., Kahn, J. M., Forlenza, C., Cho, S., Hoppe, B., Parsons, S. K., & Kelly, K. M. (2023). Children’s Oncology Group’s 2023 blueprint for research: Hodgkin lymphoma. Pediatric Blood & Cancer, 70(S6). Portico. https://doi.org/10.1002/pbc.30580

Karimi, Y., Ghesquieres, H., Jurczak, W., Cheah, C. Y., Clausen, M. R., Lugtenburg, P., Cunningham, D., Do, Y. R., Lewis, D. J., Gasiorowski, R., Kim, T. M., van der Poel, M., Poon, M. L., Feldman, T., Linton, K. M., Sureda, A., Hutchings, M., Stirner, M. C., Liu, Y., … Thieblemont, C. (2023). POSTER: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial. Clinical Lymphoma Myeloma and Leukemia, 23, S203. https://doi.org/10.1016/s2152-2650(23)00718-8

Nastoupil, L. J., Andersen, C., Ayers, A., Wang, Y., Habermann, T. M., Chihara, D., Kahl, B. S., Link, B. K., Ayyappan, S., Cohen, J. B., Martin, P., Lossos, I. S., Casulo, C., Lin, R., Li, Z., Larson, M. A., Maurer, M. J., Huynh, L., Gao, C., … Flowers, C. R. (2023). ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy. Clinical Lymphoma Myeloma and Leukemia, 23, S442–S443. https://doi.org/10.1016/s2152-2650(23)01338-1

Masaquel, A., Li, J., Ho, R., Fox, D., Rosettie, K. L., El Moustaid, F., Qu, T., & Meng, Y. (2023). POSTER: ABCL-504 Population Health and Economic Benefits of Pola-R-CHP versus R-CHOP in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in the United States. Clinical Lymphoma Myeloma and Leukemia, 23, S203. https://doi.org/10.1016/s2152-2650(23)00719-x

Konig, H., Tam, C. S., Lamanna, N., Jurczak, W., Kontos, A., Ruppert, A. S., & Tsai, D. E. (2023). POSTER: CT-168 Comparison of Bleeding-Related Events in Patients Who Received Pirtobrutinib With and Without Antithrombotic Agents. Clinical Lymphoma Myeloma and Leukemia, 23, S229. https://doi.org/10.1016/s2152-2650(23)00884-4

Lee, T. D., Aisner, D. L., David, M. P., Eno, C. C., Gagan, J., Gocke, C. D., Guseva, N. V., Haley, L., Jajosky, A. N., Jones, D., Mansukhani, M. M., Mroz, P., Murray, S. S., Newsom, K. J., Paulson, V., Roy, S., Rushton, C., Segal, J. P., Senaratne, T. N., … Kim, A. S. (2023). Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report. Blood Advances, 7(16), 4599–4607. https://doi.org/10.1182/bloodadvances.2023010149

Feng, J., Hsu, P.-F., Esteva, E., Labella, R., Wang, Y., Khodadadi-Jamayran, A., Pucella, J., Liu, C. Z., Arbini, A. A., Tsirigos, A., Kousteni, S., & Reizis, B. (2023). Haplodeficiency of the 9p21 tumor suppressor locus causes myeloid disorders driven by the bone marrow microenvironment. Blood, 142(5), 460–476. https://doi.org/10.1182/blood.2022018512

Kim, W.-S., Shortt, J., Luigi Zinzani, P., Mikhaylova, N., Marin-Niebla, A., Radeski, D., Ribrag, V., Domingo Domènech, E., Sawas, A., Alexis, K., Emig, M., Garcia, L., Overesch, A., Pietzko, K., & Horwitz, S. (2023). P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY. HemaSphere, 7(S3), e6843062. https://doi.org/10.1097/01.hs9.0000971464.68430.62

Kater, A., Harrup, R., Kipps, T. J., Eichhorst, B., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Thadani-Mulero, M., Lefebure, M., Jiang, Y., Millen, R., Boyer, M., & Seymour, J. F. (2023). S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL). HemaSphere, 7(S3), e492813f. https://doi.org/10.1097/01.hs9.0000967716.49281.3f

Mehta-Shah, N., Jacobsen, E., Luigi Zinzani, P., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter-Brown, L., Izutsu, K., Waters, S., Brammer, J., Pro, B., & Horwitz, S. (2023). P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY. HemaSphere, 7(S3), e3891642. https://doi.org/10.1097/01.hs9.0000971392.38916.42